Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

por Farnier, Michel
Publicado 2008

Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?

por Farnier, Michel
Publicado en Ann Transl Med (2018)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

por Farnier, Michel, Dong, Qian, Shah, Arvind, Johnson-Levonas, Amy O, Brudi, Philippe
Publicado 2011

Prevalence and management of hypercholesterolemia in France, the Esteban observational study

por Blacher, Jacques, Gabet, Amélie, Vallée, Alexandre, Ferrières, Jean, Bruckert, Eric, Farnier, Michel, Olié, Valérie
Publicado en Medicine (Baltimore) (2020)

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with...

por Farnier, Michel, Chen, Erluo, Johnson-Levonas, Amy O, McCrary Sisk, Christine, Mitchel, Yale B
Publicado 2014

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study

por Langslet, Gisle, Hovingh, G. Kees, Guyton, John R., Baccara-Dinet, Marie T., Letierce, Alexia, Manvelian, Garen, Farnier, Michel
Publicado en Cardiovasc Drugs Ther (2020)

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

por Viigimaa, Margus, Vaverkova, Helena, Farnier, Michel, Averna, Maurizio, Missault, Luc, Hanson, Mary E, Dong, Qian, Shah, Arvind, Brudi, Philippe
Publicado 2010

Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey

por Krempf, Michel, Simpson, Ross J, Ramey, Dena Rosen, Brudi, Philippe, Giezek, Hilde, Tomassini, Joanne E, Lee, Raymond, Farnier, Michel
Publicado en Lipids Health Dis (2015)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of...

por Kastelein, John J. P., Robinson, Jennifer G., Farnier, Michel, Krempf, Michel, Langslet, Gisle, Lorenzato, Christelle, Gipe, Daniel A., Baccara-Dinet, Marie T.
Publicado 2014

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated...

por Colhoun, Helen M, Robinson, Jennifer G, Farnier, Michel, Cariou, Bertrand, Blom, Dirk, Kereiakes, Dean J, Lorenzato, Christelle, Pordy, Robert, Chaudhari, Umesh
Publicado 2014

A case report of an acute coronary syndrome in a 10-year-old boy with homozygous familial hypercholesterolaemia

por Leclercq, Thibault, Falcon-Eicher, Sylvie, Farnier, Michel, Le Bret, Emmanuel, Maudinas, Raphaëlle, Litzler-Renault, Stéphanie, Mousson, Christiane, Lorgis, Luc, Cottin, Yves
Publicado en Eur Heart J Case Rep (2020)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

por Kastelein, John J.P., Kereiakes, Dean J., Cannon, Christopher P., Bays, Harold E., Minini, Pascal, Lee, L. Veronica, Maroni, Jaman, Farnier, Michel
Publicado en Coron Artery Dis (2017)

Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey

por Yao, Hermann, Farnier, Michel, Tribouillard, Laura, Chague, Frédéric, Brunel, Philippe, Maza, Maud, Brunet, Damien, Rochette, Luc, Bichat, Florence, Cottin, Yves, Zeller, Marianne
Publicado en Lipids Health Dis (2021)

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual...

por Harvey, Philip D, Sabbagh, Marwan N, Harrison, John E, Ginsberg, Henry N, Chapman, M John, Manvelian, Garen, Moryusef, Angele, Mandel, Jonas, Farnier, Michel
Publicado en Eur Heart J (2018)

Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management

por Sands, Bruce E, Colombel, Jean-Frédéric, Ha, Christina, Farnier, Michel, Armuzzi, Alessandro, Quirk, Daniel, Friedman, Gary S, Kwok, Kenneth, Salese, Leonardo, Su, Chinyu, Taub, Pam R
Publicado en Inflamm Bowel Dis (2020)

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies

por Ginsberg, Henry N., Farnier, Michel, Robinson, Jennifer G., Cannon, Christopher P., Sattar, Naveed, Baccara-Dinet, Marie T., Letierce, Alexia, Bujas-Bobanovic, Maja, Louie, Michael J., Colhoun, Helen M.
Publicado en Diabetes Ther (2018)

Homozygous FH Patients with Identical Mutations Variably Express the LDL Receptor: Implications for the Efficacy of Evolocumab

por Thedrez, Aurélie, Blom, Dirk J., Ramin-Mangata, Stéphane, Blanchard, Valentin, Croyal, Mikaël, Chemello, Kevin, Nativel, Brice, Pichelin, Matthieu, Cariou, Bertrand, Bourane, Steeve, Tang, Lihua, Farnier, Michel, Raal, Frederick J, Lambert, Gilles
Publicado en Arterioscler Thromb Vasc Biol (2017)

Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?

por Ghaleb, Youmna, Elbitar, Sandy, El Khoury, Petra, Bruckert, Eric, Carreau, Valérie, Carrié, Alain, Moulin, Philippe, Di-Filippo, Mathilde, Charriere, Sybil, Iliozer, Harout, Farnier, Michel, Luc, Gérald, Rabès, Jean-Pierre, Boileau, Catherine, Abifadel, Marianne, Varret, Mathilde
Publicado en Eur J Hum Genet (2018)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

por Kastelein, John J.P., Ginsberg, Henry N., Langslet, Gisle, Hovingh, G. Kees, Ceska, Richard, Dufour, Robert, Blom, Dirk, Civeira, Fernando, Krempf, Michel, Lorenzato, Christelle, Zhao, Jian, Pordy, Robert, Baccara-Dinet, Marie T., Gipe, Daniel A., Geiger, Mary Jane, Farnier, Michel
Publicado en Eur Heart J (2015)

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

por Banach, Maciej, Rizzo, Manfredi, Toth, Peter P., Farnier, Michel, Davidson, Michael H., Al-Rasadi, Khalid, Aronow, Wilbert S., Athyros, Vasilis, Djuric, Dragan M., Ezhov, Marat V., Greenfield, Robert S., Hovingh, G. Kees, Kostner, Karam, Serban, Corina, Lighezan, Daniel, Fras, Zlatko, Moriarty, Patrick M., Muntner, Paul, Goudev, Assen, Ceska, Richard, Nicholls, Stephen J., Broncel, Marlena, Nikolic, Dragana, Pella, Daniel, Puri, Raman, Rysz, Jacek, Wong, Nathan D., Bajnok, Laszlo, Jones, Steven R., Ray, Kausik K., Mikhailidis, Dimitri P.
Publicado en Arch Med Sci (2015)